カテゴリー： QYResearch, 世界, 医療/バイオ

世界の双極性障害薬＆治療市場インサイト及び予測（気分安定薬、抗けいれん薬、抗精神病薬、抗うつ薬、抗不安薬）

◆英語タイトル：Global Bipolar Disorder Drugs and Treatment Market Insights, Forecast to 2028
	◆商品コード：QY22JLX09349 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：111 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医療機器

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、双極性障害薬＆治療のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に双極性障害薬＆治療の世界市場のxxx％を占める「気分安定薬」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
双極性障害薬＆治療の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの双極性障害薬＆治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

双極性障害薬＆治療のグローバル主要企業には、AbbVie Inc.、Glaxo SmithKline (GSK)、Eli Lily and Company、Janssen Pharmaceuticals、Johnson & Johnson、Astellas Pharma Inc、Bristol Myers Squibb、Gedeon Richter PLC.、H. Lundbeck A/S、Pfizer Inc.、Novartis AG、Otsuka Holdings Co. Ltd、Validus Pharmaceuticals LLC.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

双極性障害薬＆治療市場は、種類と用途によって区分されます。世界の双極性障害薬＆治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
気分安定薬、抗けいれん薬、抗精神病薬、抗うつ薬、抗不安薬

【用途別セグメント】
病院、診療所

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 双極性障害薬＆治療製品概要
- 種類別市場（気分安定薬、抗けいれん薬、抗精神病薬、抗うつ薬、抗不安薬）
- 用途別市場（病院、診療所）
- 調査の目的
・エグゼクティブサマリー
- 世界の双極性障害薬＆治療販売量予測2017-2028
- 世界の双極性障害薬＆治療売上予測2017-2028
- 双極性障害薬＆治療の地域別販売量
- 双極性障害薬＆治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別双極性障害薬＆治療販売量
- 主要メーカー別双極性障害薬＆治療売上
- 主要メーカー別双極性障害薬＆治療価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（気分安定薬、抗けいれん薬、抗精神病薬、抗うつ薬、抗不安薬）
- 双極性障害薬＆治療の種類別販売量
- 双極性障害薬＆治療の種類別売上
- 双極性障害薬＆治療の種類別価格
・用途別市場規模（病院、診療所）
- 双極性障害薬＆治療の用途別販売量
- 双極性障害薬＆治療の用途別売上
- 双極性障害薬＆治療の用途別価格
・北米市場
- 北米の双極性障害薬＆治療市場規模（種類別、用途別）
- 主要国別の双極性障害薬＆治療市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの双極性障害薬＆治療市場規模（種類別、用途別）
- 主要国別の双極性障害薬＆治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の双極性障害薬＆治療市場規模（種類別、用途別）
- 主要国別の双極性障害薬＆治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の双極性障害薬＆治療市場規模（種類別、用途別）
- 主要国別の双極性障害薬＆治療市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの双極性障害薬＆治療市場規模（種類別、用途別）
- 主要国別の双極性障害薬＆治療市場規模（トルコ、サウジアラビア）
・企業情報
AbbVie Inc.、Glaxo SmithKline (GSK)、Eli Lily and Company、Janssen Pharmaceuticals、Johnson & Johnson、Astellas Pharma Inc、Bristol Myers Squibb、Gedeon Richter PLC.、H. Lundbeck A/S、Pfizer Inc.、Novartis AG、Otsuka Holdings Co. Ltd、Validus Pharmaceuticals LLC.
・産業チェーン及び販売チャネル分析
- 双極性障害薬＆治療の産業チェーン分析
- 双極性障害薬＆治療の原材料
- 双極性障害薬＆治療の生産プロセス
- 双極性障害薬＆治療の販売及びマーケティング
- 双極性障害薬＆治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 双極性障害薬＆治療の産業動向
- 双極性障害薬＆治療のマーケットドライバー
- 双極性障害薬＆治療の課題
- 双極性障害薬＆治療の阻害要因
・主な調査結果

Drug therapy is currently the core method of treating bipolar disorder, that is, the use of emotional stabilizers to adjust the patient’s mood. Bipolar disorder is complex and difficult to control. The drug effect of emotional stabilizers can help patients to suppress their emotions when they are too high, to increase their emotions when they are depressed, to stabilize their emotions at a normal level, and to effectively prevent the recurrence of bipolar disorder. The quickest and most effective approach may be convulsive-free electroconvulsive therapy.
Market Analysis and Insights: Global Bipolar Disorder Drugs and Treatment Market
Due to the COVID-19 pandemic, the global Bipolar Disorder Drugs and Treatment market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Mood Stabilizers accounting for % of the Bipolar Disorder Drugs and Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Bipolar Disorder Drugs and Treatment market size is valued at US$ million in 2021, while the US and Europe Bipolar Disorder Drugs and Treatment are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Bipolar Disorder Drugs and Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Bipolar Disorder Drugs and Treatment include AbbVie Inc., Glaxo SmithKline (GSK), Eli Lily and Company, Janssen Pharmaceuticals, Johnson & Johnson, Astellas Pharma Inc, Bristol Myers Squibb, Gedeon Richter PLC. and H. Lundbeck A/S, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Bipolar Disorder Drugs and Treatment Scope and Segment
Bipolar Disorder Drugs and Treatment market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Bipolar Disorder Drugs and Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Mood Stabilizers
Anticonvulsants
Antipsychotic Drugs
Antidepressant Drugs
Anti-Anxiety Drugs
Segment by Application
Hospital
Clinic
By Company
AbbVie Inc.
Glaxo SmithKline (GSK)
Eli Lily and Company
Janssen Pharmaceuticals
Johnson & Johnson
Astellas Pharma Inc
Bristol Myers Squibb
Gedeon Richter PLC.
H. Lundbeck A/S
Pfizer Inc.
Novartis AG
Otsuka Holdings Co. Ltd
Validus Pharmaceuticals LLC.
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Bipolar Disorder Drugs and Treatment Product Introduction
1.2 Market by Type
1.2.1 Global Bipolar Disorder Drugs and Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Mood Stabilizers
1.2.3 Anticonvulsants
1.2.4 Antipsychotic Drugs
1.2.5 Antidepressant Drugs
1.2.6 Anti-Anxiety Drugs
1.3 Market by Application
1.3.1 Global Bipolar Disorder Drugs and Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Bipolar Disorder Drugs and Treatment Sales Estimates and Forecasts 2017-2028
2.2 Global Bipolar Disorder Drugs and Treatment Revenue Estimates and Forecasts 2017-2028
2.3 Global Bipolar Disorder Drugs and Treatment Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Bipolar Disorder Drugs and Treatment Sales by Region
2.4.1 Global Bipolar Disorder Drugs and Treatment Sales by Region (2017-2022)
2.4.2 Global Sales Bipolar Disorder Drugs and Treatment by Region (2023-2028)
2.5 Global Bipolar Disorder Drugs and Treatment Revenue by Region
2.5.1 Global Bipolar Disorder Drugs and Treatment Revenue by Region (2017-2022)
2.5.2 Global Bipolar Disorder Drugs and Treatment Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Bipolar Disorder Drugs and Treatment Sales by Manufacturers
3.1.1 Global Top Bipolar Disorder Drugs and Treatment Manufacturers by Sales (2017-2022)
3.1.2 Global Bipolar Disorder Drugs and Treatment Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Bipolar Disorder Drugs and Treatment in 2021
3.2 Global Bipolar Disorder Drugs and Treatment Revenue by Manufacturers
3.2.1 Global Bipolar Disorder Drugs and Treatment Revenue by Manufacturers (2017-2022)
3.2.2 Global Bipolar Disorder Drugs and Treatment Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Bipolar Disorder Drugs and Treatment Revenue in 2021
3.3 Global Bipolar Disorder Drugs and Treatment Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Bipolar Disorder Drugs and Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Bipolar Disorder Drugs and Treatment Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Bipolar Disorder Drugs and Treatment Sales by Type
4.1.1 Global Bipolar Disorder Drugs and Treatment Historical Sales by Type (2017-2022)
4.1.2 Global Bipolar Disorder Drugs and Treatment Forecasted Sales by Type (2023-2028)
4.1.3 Global Bipolar Disorder Drugs and Treatment Sales Market Share by Type (2017-2028)
4.2 Global Bipolar Disorder Drugs and Treatment Revenue by Type
4.2.1 Global Bipolar Disorder Drugs and Treatment Historical Revenue by Type (2017-2022)
4.2.2 Global Bipolar Disorder Drugs and Treatment Forecasted Revenue by Type (2023-2028)
4.2.3 Global Bipolar Disorder Drugs and Treatment Revenue Market Share by Type (2017-2028)
4.3 Global Bipolar Disorder Drugs and Treatment Price by Type
4.3.1 Global Bipolar Disorder Drugs and Treatment Price by Type (2017-2022)
4.3.2 Global Bipolar Disorder Drugs and Treatment Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Bipolar Disorder Drugs and Treatment Sales by Application
5.1.1 Global Bipolar Disorder Drugs and Treatment Historical Sales by Application (2017-2022)
5.1.2 Global Bipolar Disorder Drugs and Treatment Forecasted Sales by Application (2023-2028)
5.1.3 Global Bipolar Disorder Drugs and Treatment Sales Market Share by Application (2017-2028)
5.2 Global Bipolar Disorder Drugs and Treatment Revenue by Application
5.2.1 Global Bipolar Disorder Drugs and Treatment Historical Revenue by Application (2017-2022)
5.2.2 Global Bipolar Disorder Drugs and Treatment Forecasted Revenue by Application (2023-2028)
5.2.3 Global Bipolar Disorder Drugs and Treatment Revenue Market Share by Application (2017-2028)
5.3 Global Bipolar Disorder Drugs and Treatment Price by Application
5.3.1 Global Bipolar Disorder Drugs and Treatment Price by Application (2017-2022)
5.3.2 Global Bipolar Disorder Drugs and Treatment Price Forecast by Application (2023-2028)
6 North America
6.1 North America Bipolar Disorder Drugs and Treatment Market Size by Type
6.1.1 North America Bipolar Disorder Drugs and Treatment Sales by Type (2017-2028)
6.1.2 North America Bipolar Disorder Drugs and Treatment Revenue by Type (2017-2028)
6.2 North America Bipolar Disorder Drugs and Treatment Market Size by Application
6.2.1 North America Bipolar Disorder Drugs and Treatment Sales by Application (2017-2028)
6.2.2 North America Bipolar Disorder Drugs and Treatment Revenue by Application (2017-2028)
6.3 North America Bipolar Disorder Drugs and Treatment Market Size by Country
6.3.1 North America Bipolar Disorder Drugs and Treatment Sales by Country (2017-2028)
6.3.2 North America Bipolar Disorder Drugs and Treatment Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Bipolar Disorder Drugs and Treatment Market Size by Type
7.1.1 Europe Bipolar Disorder Drugs and Treatment Sales by Type (2017-2028)
7.1.2 Europe Bipolar Disorder Drugs and Treatment Revenue by Type (2017-2028)
7.2 Europe Bipolar Disorder Drugs and Treatment Market Size by Application
7.2.1 Europe Bipolar Disorder Drugs and Treatment Sales by Application (2017-2028)
7.2.2 Europe Bipolar Disorder Drugs and Treatment Revenue by Application (2017-2028)
7.3 Europe Bipolar Disorder Drugs and Treatment Market Size by Country
7.3.1 Europe Bipolar Disorder Drugs and Treatment Sales by Country (2017-2028)
7.3.2 Europe Bipolar Disorder Drugs and Treatment Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Bipolar Disorder Drugs and Treatment Market Size by Type
8.1.1 Asia Pacific Bipolar Disorder Drugs and Treatment Sales by Type (2017-2028)
8.1.2 Asia Pacific Bipolar Disorder Drugs and Treatment Revenue by Type (2017-2028)
8.2 Asia Pacific Bipolar Disorder Drugs and Treatment Market Size by Application
8.2.1 Asia Pacific Bipolar Disorder Drugs and Treatment Sales by Application (2017-2028)
8.2.2 Asia Pacific Bipolar Disorder Drugs and Treatment Revenue by Application (2017-2028)
8.3 Asia Pacific Bipolar Disorder Drugs and Treatment Market Size by Region
8.3.1 Asia Pacific Bipolar Disorder Drugs and Treatment Sales by Region (2017-2028)
8.3.2 Asia Pacific Bipolar Disorder Drugs and Treatment Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Bipolar Disorder Drugs and Treatment Market Size by Type
9.1.1 Latin America Bipolar Disorder Drugs and Treatment Sales by Type (2017-2028)
9.1.2 Latin America Bipolar Disorder Drugs and Treatment Revenue by Type (2017-2028)
9.2 Latin America Bipolar Disorder Drugs and Treatment Market Size by Application
9.2.1 Latin America Bipolar Disorder Drugs and Treatment Sales by Application (2017-2028)
9.2.2 Latin America Bipolar Disorder Drugs and Treatment Revenue by Application (2017-2028)
9.3 Latin America Bipolar Disorder Drugs and Treatment Market Size by Country
9.3.1 Latin America Bipolar Disorder Drugs and Treatment Sales by Country (2017-2028)
9.3.2 Latin America Bipolar Disorder Drugs and Treatment Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Bipolar Disorder Drugs and Treatment Market Size by Type
10.1.1 Middle East and Africa Bipolar Disorder Drugs and Treatment Sales by Type (2017-2028)
10.1.2 Middle East and Africa Bipolar Disorder Drugs and Treatment Revenue by Type (2017-2028)
10.2 Middle East and Africa Bipolar Disorder Drugs and Treatment Market Size by Application
10.2.1 Middle East and Africa Bipolar Disorder Drugs and Treatment Sales by Application (2017-2028)
10.2.2 Middle East and Africa Bipolar Disorder Drugs and Treatment Revenue by Application (2017-2028)
10.3 Middle East and Africa Bipolar Disorder Drugs and Treatment Market Size by Country
10.3.1 Middle East and Africa Bipolar Disorder Drugs and Treatment Sales by Country (2017-2028)
10.3.2 Middle East and Africa Bipolar Disorder Drugs and Treatment Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Corporation Information
11.1.2 AbbVie Inc. Overview
11.1.3 AbbVie Inc. Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 AbbVie Inc. Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AbbVie Inc. Recent Developments
11.2 Glaxo SmithKline (GSK)
11.2.1 Glaxo SmithKline (GSK) Corporation Information
11.2.2 Glaxo SmithKline (GSK) Overview
11.2.3 Glaxo SmithKline (GSK) Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Glaxo SmithKline (GSK) Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Glaxo SmithKline (GSK) Recent Developments
11.3 Eli Lily and Company
11.3.1 Eli Lily and Company Corporation Information
11.3.2 Eli Lily and Company Overview
11.3.3 Eli Lily and Company Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Eli Lily and Company Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Eli Lily and Company Recent Developments
11.4 Janssen Pharmaceuticals
11.4.1 Janssen Pharmaceuticals Corporation Information
11.4.2 Janssen Pharmaceuticals Overview
11.4.3 Janssen Pharmaceuticals Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Janssen Pharmaceuticals Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Janssen Pharmaceuticals Recent Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Corporation Information
11.5.2 Johnson & Johnson Overview
11.5.3 Johnson & Johnson Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Johnson & Johnson Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Johnson & Johnson Recent Developments
11.6 Astellas Pharma Inc
11.6.1 Astellas Pharma Inc Corporation Information
11.6.2 Astellas Pharma Inc Overview
11.6.3 Astellas Pharma Inc Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Astellas Pharma Inc Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Astellas Pharma Inc Recent Developments
11.7 Bristol Myers Squibb
11.7.1 Bristol Myers Squibb Corporation Information
11.7.2 Bristol Myers Squibb Overview
11.7.3 Bristol Myers Squibb Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Bristol Myers Squibb Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Bristol Myers Squibb Recent Developments
11.8 Gedeon Richter PLC.
11.8.1 Gedeon Richter PLC. Corporation Information
11.8.2 Gedeon Richter PLC. Overview
11.8.3 Gedeon Richter PLC. Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Gedeon Richter PLC. Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Gedeon Richter PLC. Recent Developments
11.9 H. Lundbeck A/S
11.9.1 H. Lundbeck A/S Corporation Information
11.9.2 H. Lundbeck A/S Overview
11.9.3 H. Lundbeck A/S Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 H. Lundbeck A/S Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 H. Lundbeck A/S Recent Developments
11.10 Pfizer Inc.
11.10.1 Pfizer Inc. Corporation Information
11.10.2 Pfizer Inc. Overview
11.10.3 Pfizer Inc. Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Pfizer Inc. Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Pfizer Inc. Recent Developments
11.11 Novartis AG
11.11.1 Novartis AG Corporation Information
11.11.2 Novartis AG Overview
11.11.3 Novartis AG Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Novartis AG Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Novartis AG Recent Developments
11.12 Otsuka Holdings Co. Ltd
11.12.1 Otsuka Holdings Co. Ltd Corporation Information
11.12.2 Otsuka Holdings Co. Ltd Overview
11.12.3 Otsuka Holdings Co. Ltd Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Otsuka Holdings Co. Ltd Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Otsuka Holdings Co. Ltd Recent Developments
11.13 Validus Pharmaceuticals LLC.
11.13.1 Validus Pharmaceuticals LLC. Corporation Information
11.13.2 Validus Pharmaceuticals LLC. Overview
11.13.3 Validus Pharmaceuticals LLC. Bipolar Disorder Drugs and Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Validus Pharmaceuticals LLC. Bipolar Disorder Drugs and Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Validus Pharmaceuticals LLC. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Bipolar Disorder Drugs and Treatment Industry Chain Analysis
12.2 Bipolar Disorder Drugs and Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Bipolar Disorder Drugs and Treatment Production Mode & Process
12.4 Bipolar Disorder Drugs and Treatment Sales and Marketing
12.4.1 Bipolar Disorder Drugs and Treatment Sales Channels
12.4.2 Bipolar Disorder Drugs and Treatment Distributors
12.5 Bipolar Disorder Drugs and Treatment Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Bipolar Disorder Drugs and Treatment Industry Trends
13.2 Bipolar Disorder Drugs and Treatment Market Drivers
13.3 Bipolar Disorder Drugs and Treatment Market Challenges
13.4 Bipolar Disorder Drugs and Treatment Market Restraints
14 Key Findings in The Global Bipolar Disorder Drugs and Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の双極性障害薬＆治療市場インサイト及び予測（気分安定薬、抗けいれん薬、抗精神病薬、抗うつ薬、抗不安薬）(Global Bipolar Disorder Drugs and Treatment Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の双極性障害薬＆治療市場インサイト及び予測（気分安定薬、抗けいれん薬、抗精神病薬、抗うつ薬、抗不安薬）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp